Download PDF
Kardiologie up2date 2013; 09(03): 165-171
DOI: 10.1055/s-0033-1344650
Hotline – Thrombozyten und Gerinnungssystem bei kardiovaskulären Erkrankungen
© Georg Thieme Verlag KG Stuttgart · New York

Loading mit Thrombozytenaggregationshemmern beim akuten Koronarsyndrom

Michal Droppa
,
Tobias Geisler
Further Information

Publication History

Publication Date:
27 September 2013 (online)

Also available at
    Permissions and Reprints All articles of this category

Abstract

Dual antiplatelet therapy with aspirin and P2Y12 receptor inhibitor is a cornerstone of medical treatment in patients with acute coronary syndrome. With loading dose a faster effect and higher plasma concentration of given drug can be achieved. It could be shown that loading with P2Y12 inhibitor reduces major adverse cardiac events after percutaneous coronary intervention. Thus, loading is generally recommended in patients with acute coronary syndrome. Clinical benefit of early prehospital loading and upstream therapy, on mortality could be shown for patients with STEMI, however not for patients with NSTEMI and unstable angina pectoris. A clinical risk-score like GRACE-Score and the CRUSADE bleeding score can be used to identify patients at high risk in UA/NSTEMI-patients who might benefit from early upstream therapy.

 

  • Literatur

  • 1 Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054
    CrossrefPubMedGoogle Scholar
  • 2 Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569-2619
    CrossrefPubMedGoogle Scholar
  • 3 Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
    CrossrefPubMedGoogle Scholar
  • 4 Steinhubl SR, Berger PB, Mann JT 3rd et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002; 288: 2411-2420
    CrossrefPubMedGoogle Scholar
  • 5 Montalescot G, Sideris G, Meuleman C et al. A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) Trial. J Am Coll Cardiol 2006; 48: 931-938
    CrossrefPubMedGoogle Scholar
  • 6 Beckerath von N, Taubert D, Pogatsa-Murray G et al. Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005; 112: 2946-2950
    PubMedGoogle Scholar
  • 7 Mehta SR, Tanguay JF, Eikelboom JW et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376: 1233-1243
    CrossrefPubMedGoogle Scholar
  • 8 Patti G, Bárczi G, Orlic D et al. Outcome Comparison of 600- and 300-mg Loading Doses of Clopidogrel in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: Results From the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) Randomized Study. J Am Coll Cardiol 2011; 58: 1592-1599
    CrossrefPubMedGoogle Scholar
  • 9 Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007; 357: 2001-2015
    CrossrefPubMedGoogle Scholar
  • 10 Gurbel PA, Bliden KP, Butler K et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577-2585
    CrossrefPubMedGoogle Scholar
  • 11 Wallentin L, Becker RC, Budaj A. PLATO Investigators et al. Freij A, Thorsén M Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057
    CrossrefPubMedGoogle Scholar
  • 12 Frossard M, Fuchs I, Leitner JM et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004; 110: 1392-1397
    CrossrefPubMedGoogle Scholar
  • 13 Fuchs I, Frossard M, Spiel A et al. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 2006; 4: 2547-2552
    CrossrefPubMedGoogle Scholar
  • 14 Ferreiro JL, Homs S, Berdejo J et al. Clopidogrel pretreatment in primary percutaneous coronary intervention: Prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery. Thromb Haemost 2013; 110: 110-117
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Koul S, Smith JG, Scherstén F et al. Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J 2011; 32: 2989-2997
    CrossrefPubMedGoogle Scholar
  • 16 Alexopoulos D, Xanthopoulou I, Gkizas V et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012; 5: 797-804
    CrossrefPubMedGoogle Scholar
  • 17 Zeymer U, Arntz HR, Mark B et al. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol 2012; 101: 305-312
    CrossrefPubMedGoogle Scholar
  • 18 Montalescot G, Lassen JF, Hamm CW et al. Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study. Am Heart J 2013; 165: 515-522
    CrossrefPubMedGoogle Scholar
  • 19 Sabatine MS, Hamdalla HN, Mehta SR et al. Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. Am Heart J 2008; 155: 910-917
    CrossrefPubMedGoogle Scholar
  • 20 Bellemain-Appaix A, O'Connor SA, Silvain J. ACTION Group et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA 2012; 308: 2507-2516
    CrossrefPubMedGoogle Scholar
  • 21 Montalescot G, Bolognese L, Dudek D et al. for the ACCOAST Investigators. Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes. N Engl J Med 2013; 369: 999-1010
    CrossrefPubMedGoogle Scholar
  • 22 Cannon CP, Harrington RA, James S et al. PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375: 283-293 DOI: 10.1016/S0140-6736(09)62191-7.
    CrossrefPubMedGoogle Scholar
  • 23 Boersma E, Harrington RA, Moliterno DJ et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189-198
    CrossrefPubMedGoogle Scholar
  • 24 Ebrahimi R, Dyke C, Mehran R et al. Outcomes Following Pre-Operative Clopidogrel Administration in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery: The ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial. J Am Coll Cardiol 2009; 53: 1965-1972
    CrossrefPubMedGoogle Scholar
  • 25 Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
    CrossrefPubMedGoogle Scholar
  • 26 Wijns W, Kolh P. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI) et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-2555
    CrossrefPubMedGoogle Scholar
  • 27 Smith PK, Goodnough LT, Levy JH et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol 2012; 60: 388-396
    CrossrefPubMedGoogle Scholar
  • 28 Held C, Asenblad N, Bassand JP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011; 57: 672-684
    CrossrefPubMedGoogle Scholar
  • 29 Bhatt DL, Stone GW, Mahaffey KW. CHAMPION PHOENIX Investigators et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368: 1303-1313
    CrossrefPubMedGoogle Scholar
  • 30 Angiolillo DJ, Firstenberg MS, Price MJ. BRIDGE Investigators et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012; 307: 265-274
    CrossrefPubMedGoogle Scholar
  • 31 Montalescot G, Sideris G, Cohen R et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 2010; 103: 213-223
    PubMedGoogle Scholar
  • 32 Angiolillo DJ, Saucedo JF, Deraad R et al. SWAP Investigators Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 2010; 56: 1017-1023
    CrossrefPubMedGoogle Scholar
  • 33 Steinhubl SR, Oh JJ, Oestreich JH et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 2008; 121: 527-534
    CrossrefPubMedGoogle Scholar
  • 34 Dovlatova NL, Jakubowski JA, Sugidachi A et al. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 2008; 6: 1153-1159
    CrossrefPubMedGoogle Scholar